219 related articles for article (PubMed ID: 34998916)
1. Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy.
Ni Q; Xu F; Wang Y; Li Y; Qing G; Zhang Y; Zhong J; Li J; Liang XJ
J Control Release; 2022 Feb; 342():210-227. PubMed ID: 34998916
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
4. Nanomaterials for T-cell cancer immunotherapy.
Gong N; Sheppard NC; Billingsley MM; June CH; Mitchell MJ
Nat Nanotechnol; 2021 Jan; 16(1):25-36. PubMed ID: 33437036
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
Li L; Yang Z; Chen X
Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
[TBL] [Abstract][Full Text] [Related]
6. Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy.
Xing H; Li X
Chemistry; 2024 Jun; 30(32):e202400425. PubMed ID: 38576219
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
8. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
9. Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy.
Le QV; Suh J; Oh YK
AAPS J; 2019 May; 21(4):64. PubMed ID: 31102154
[TBL] [Abstract][Full Text] [Related]
10. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
[TBL] [Abstract][Full Text] [Related]
12. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy.
Chen Z; Pan H; Luo Y; Yin T; Zhang B; Liao J; Wang M; Tang X; Huang G; Deng G; Zheng M; Cai L
Small; 2021 Apr; 17(14):e2007494. PubMed ID: 33711191
[TBL] [Abstract][Full Text] [Related]
13. Nanomaterials: Breaking through the bottleneck of tumor immunotherapy.
Kang Y; Li S
Int J Biol Macromol; 2023 Mar; 230():123159. PubMed ID: 36610572
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?
Greenbaum U; Yalniz FF; Srour SA; Rezvani K; Singh H; Olson A; Blumenschein G; Hong DS; Shpall EJ; Kebriaei P
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1759-1769. PubMed ID: 32623078
[TBL] [Abstract][Full Text] [Related]
15. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
16. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fucà G; Reppel L; Landoni E; Savoldo B; Dotti G
Clin Cancer Res; 2020 Jun; 26(11):2444-2451. PubMed ID: 32015021
[TBL] [Abstract][Full Text] [Related]
17. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
18. Nanomaterials for cancer immunotherapy.
Song W; Musetti SN; Huang L
Biomaterials; 2017 Dec; 148():16-30. PubMed ID: 28961532
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
20. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
